This Immunofluorescence Assay market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The immunofluorescence assay market size has grown strongly in recent years. It will grow from $3.34 billion in 2024 to $3.59 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increased disease diagnosis, rise in research and development, rise in autoimmune diseases, increased cancer diagnostics, rise in virology research.
The immunofluorescence assay market size is expected to see rapid growth in the next few years. It will grow to $5.4 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increasing personalized medicine, rising infectious disease surveillance, rising autoimmune disorders, rising point-of-care testing, increasing global health preparedness. Major trends in the forecast period include multiplexing assays, automation and robotics, high-content imaging, advanced fluorophores, digital pathology integration.
The robust growth of the immunofluorescence assay market is significantly attributed to the increasing prevalence of chronic diseases. Lifestyle changes, dietary habits, and inadequate weight management contribute to a surge in chronic conditions, with prolonged infections posing a risk of developing cancer. Immunofluorescence assays are witnessing heightened demand for their extensive use in the diagnosis and drug development activities associated with chronic diseases. A study from the Centers for Disease Control and Prevention reveals that around 6 in 10 adults in the USA are affected by chronic diseases, accounting for a substantial annual healthcare cost of $3.8 trillion. Therefore, the escalating prevalence of chronic diseases is anticipated to drive the demand for immunofluorescence assays throughout the forecast period.
The immunofluorescence assay market is poised for further growth due to the increasing demand for personalized medicines. Personalized medicine, utilizing an individual's genetic profile to inform decisions related to disease prevention, diagnosis, and treatment, relies heavily on immunofluorescence assays. These assays play a pivotal role in identifying specific biomarkers crucial for formulating personalized treatment plans. The Personalized Medicine Coalition reports that over 75,000 genetic testing products and 300 personalized medicines will be available for various conditions, including cancer, rare genetic diseases, and chronic and infectious diseases. Consequently, the rising demand for personalized medicines is propelling the growth of the immunofluorescence assay market.
A prominent trend in the immunofluorescence assay market is the emphasis on technological advancements. Companies in this sector are dedicated to developing innovative products with advanced technologies, especially for diagnostic purposes related to emerging viruses like COVID-19. LumiraDx, a UK-based developer of point-of-care diagnostics, received emergency approval for its microfluidic immunofluorescence assay, LumiraDx SARS-CoV-2 Ag Test, designed for the qualitative detection of nucleocapsid protein antigens from nasal swab samples in March 2022.
Major players in the immunofluorescence assay market are strategically focusing on introducing fully automated solutions to maximize their market revenues. Fully automated solutions streamline the entire immunofluorescence testing process, from sample preparation to incubation, washing, and slide mounting. Revvity Inc., a US-based life sciences and diagnostics company, launched UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics in June 2023. UNIQO 160, a tabletop device, integrates automated processing with a high-quality microscope, capable of handling up to 160 main samples and 18 slides in a single run. The system utilizes barcode recognition for individual samples, reagents, and slides.
In January 2022, Thermo Fisher Scientific Inc., a US-based biotechnology firm, acquired PeproTech Inc. for $1.85 billion. This acquisition is intended to enhance Thermo Fisher Scientific Inc.'s ability to support its pharmaceutical and biotech clients by integrating new capabilities into its biosciences business, which is essential for the changing landscape of gene therapies. PeproTech Inc. is a US-based life science company that offers recombinant proteins and ELISA immunofluorescence kits.
Major companies operating in the immunofluorescence assay market include Thermo Fisher Scientific Inc., Abcam plc, Bio-Rad Laboratories Inc., PerkinElmer Inc., Werfen Company, Merck KGaA, Danaher Corporation, Cell Signaling Technology Inc., Vector Laboratories Inc., INOVA Diagnostics Inc., Sino Biological Inc., Medipan GmbH, BioLegend Inc., Jackson ImmunoResearch Laboratories Inc., Rockland Immunochemicals Inc., Bethyl Laboratories Inc., Fitzgerald Industries International Inc., Creative Diagnostics, Boster Biological Technology, Acris Antibodies GmbH, RayBiotech Inc., Proteintech Group Inc., Novus Biologicals LLC, R&D Systems Inc., OriGene Technologies Inc., GenScript Biotech Corporation, MBL International Corporation, Abnova Corporation, Cellabs India Technologies Limited, J. Mitra & Co. Pvt. Ltd., EpiGentek Group Inc., Elabscience Biotechnology Co. Ltd., Aesku.Diagnostics GmbH.
North America was the largest region in the immunofluorescence assay market in 2024, and it is also expected to be the fastest-growing region in the forecast period. The regions covered in the immunofluorescence assay market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the immunofluorescence assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
Immunofluorescence assay encompasses both equipment and consumables designed to utilize a technique allowing the visualization of specific proteins and antigens in infected cells. This visualization is achieved through the reaction of these proteins and antigens with specific antibodies, which are chemically conjugated with a fluorescent dye. This laboratory technique is employed in the diagnosis of diseases affecting various organ systems such as the skin, kidney, heart, cilia, and others.
The main types of immunofluorescence assay include direct immunofluorescence and indirect immunofluorescence. Direct immunofluorescence is a laboratory technique specifically used for diagnosing diseases related to the skin, kidney, and other organ systems. In this method, a single antibody directly conjugated to a fluorescent dye is utilized. The diverse range of products in the immunofluorescence assay category includes reagents, instruments, antibodies, kits, consumables, and accessories. These products are employed in the diagnosis of various diseases, including cancer, infectious diseases, autoimmune diseases, among others. Immunofluorescence assay products are utilized by academic and research institutions, pharmaceutical and biotechnology companies, hospitals and diagnostic centers, as well as contract research organizations.
The immunofluorescence assay market research report is one of a series of new reports that provides immunofluorescence assay market statistics, including immunofluorescence assay industry global market size, regional shares, competitors with an immunofluorescence assay market share, detailed immunofluorescence assay market segments, market trends and opportunities, and any further data you may need to thrive in the immunofluorescence assay industry. This immunofluorescence assay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The immunofluorescence assay market consists of sales of indirect IF complement-fixation (IF-CF), and double IF. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The immunofluorescence assay market size has grown strongly in recent years. It will grow from $3.34 billion in 2024 to $3.59 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increased disease diagnosis, rise in research and development, rise in autoimmune diseases, increased cancer diagnostics, rise in virology research.
The immunofluorescence assay market size is expected to see rapid growth in the next few years. It will grow to $5.4 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increasing personalized medicine, rising infectious disease surveillance, rising autoimmune disorders, rising point-of-care testing, increasing global health preparedness. Major trends in the forecast period include multiplexing assays, automation and robotics, high-content imaging, advanced fluorophores, digital pathology integration.
The robust growth of the immunofluorescence assay market is significantly attributed to the increasing prevalence of chronic diseases. Lifestyle changes, dietary habits, and inadequate weight management contribute to a surge in chronic conditions, with prolonged infections posing a risk of developing cancer. Immunofluorescence assays are witnessing heightened demand for their extensive use in the diagnosis and drug development activities associated with chronic diseases. A study from the Centers for Disease Control and Prevention reveals that around 6 in 10 adults in the USA are affected by chronic diseases, accounting for a substantial annual healthcare cost of $3.8 trillion. Therefore, the escalating prevalence of chronic diseases is anticipated to drive the demand for immunofluorescence assays throughout the forecast period.
The immunofluorescence assay market is poised for further growth due to the increasing demand for personalized medicines. Personalized medicine, utilizing an individual's genetic profile to inform decisions related to disease prevention, diagnosis, and treatment, relies heavily on immunofluorescence assays. These assays play a pivotal role in identifying specific biomarkers crucial for formulating personalized treatment plans. The Personalized Medicine Coalition reports that over 75,000 genetic testing products and 300 personalized medicines will be available for various conditions, including cancer, rare genetic diseases, and chronic and infectious diseases. Consequently, the rising demand for personalized medicines is propelling the growth of the immunofluorescence assay market.
A prominent trend in the immunofluorescence assay market is the emphasis on technological advancements. Companies in this sector are dedicated to developing innovative products with advanced technologies, especially for diagnostic purposes related to emerging viruses like COVID-19. LumiraDx, a UK-based developer of point-of-care diagnostics, received emergency approval for its microfluidic immunofluorescence assay, LumiraDx SARS-CoV-2 Ag Test, designed for the qualitative detection of nucleocapsid protein antigens from nasal swab samples in March 2022.
Major players in the immunofluorescence assay market are strategically focusing on introducing fully automated solutions to maximize their market revenues. Fully automated solutions streamline the entire immunofluorescence testing process, from sample preparation to incubation, washing, and slide mounting. Revvity Inc., a US-based life sciences and diagnostics company, launched UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics in June 2023. UNIQO 160, a tabletop device, integrates automated processing with a high-quality microscope, capable of handling up to 160 main samples and 18 slides in a single run. The system utilizes barcode recognition for individual samples, reagents, and slides.
In January 2022, Thermo Fisher Scientific Inc., a US-based biotechnology firm, acquired PeproTech Inc. for $1.85 billion. This acquisition is intended to enhance Thermo Fisher Scientific Inc.'s ability to support its pharmaceutical and biotech clients by integrating new capabilities into its biosciences business, which is essential for the changing landscape of gene therapies. PeproTech Inc. is a US-based life science company that offers recombinant proteins and ELISA immunofluorescence kits.
Major companies operating in the immunofluorescence assay market include Thermo Fisher Scientific Inc., Abcam plc, Bio-Rad Laboratories Inc., PerkinElmer Inc., Werfen Company, Merck KGaA, Danaher Corporation, Cell Signaling Technology Inc., Vector Laboratories Inc., INOVA Diagnostics Inc., Sino Biological Inc., Medipan GmbH, BioLegend Inc., Jackson ImmunoResearch Laboratories Inc., Rockland Immunochemicals Inc., Bethyl Laboratories Inc., Fitzgerald Industries International Inc., Creative Diagnostics, Boster Biological Technology, Acris Antibodies GmbH, RayBiotech Inc., Proteintech Group Inc., Novus Biologicals LLC, R&D Systems Inc., OriGene Technologies Inc., GenScript Biotech Corporation, MBL International Corporation, Abnova Corporation, Cellabs India Technologies Limited, J. Mitra & Co. Pvt. Ltd., EpiGentek Group Inc., Elabscience Biotechnology Co. Ltd., Aesku.Diagnostics GmbH.
North America was the largest region in the immunofluorescence assay market in 2024, and it is also expected to be the fastest-growing region in the forecast period. The regions covered in the immunofluorescence assay market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the immunofluorescence assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
Immunofluorescence assay encompasses both equipment and consumables designed to utilize a technique allowing the visualization of specific proteins and antigens in infected cells. This visualization is achieved through the reaction of these proteins and antigens with specific antibodies, which are chemically conjugated with a fluorescent dye. This laboratory technique is employed in the diagnosis of diseases affecting various organ systems such as the skin, kidney, heart, cilia, and others.
The main types of immunofluorescence assay include direct immunofluorescence and indirect immunofluorescence. Direct immunofluorescence is a laboratory technique specifically used for diagnosing diseases related to the skin, kidney, and other organ systems. In this method, a single antibody directly conjugated to a fluorescent dye is utilized. The diverse range of products in the immunofluorescence assay category includes reagents, instruments, antibodies, kits, consumables, and accessories. These products are employed in the diagnosis of various diseases, including cancer, infectious diseases, autoimmune diseases, among others. Immunofluorescence assay products are utilized by academic and research institutions, pharmaceutical and biotechnology companies, hospitals and diagnostic centers, as well as contract research organizations.
The immunofluorescence assay market research report is one of a series of new reports that provides immunofluorescence assay market statistics, including immunofluorescence assay industry global market size, regional shares, competitors with an immunofluorescence assay market share, detailed immunofluorescence assay market segments, market trends and opportunities, and any further data you may need to thrive in the immunofluorescence assay industry. This immunofluorescence assay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The immunofluorescence assay market consists of sales of indirect IF complement-fixation (IF-CF), and double IF. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Immunofluorescence Assay Market Characteristics3. Immunofluorescence Assay Market Trends and Strategies4. Immunofluorescence Assay Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Immunofluorescence Assay Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Immunofluorescence Assay Market34. Recent Developments in the Immunofluorescence Assay Market
5. Global Immunofluorescence Assay Growth Analysis and Strategic Analysis Framework
6. Immunofluorescence Assay Market Segmentation
7. Immunofluorescence Assay Market Regional and Country Analysis
8. Asia-Pacific Immunofluorescence Assay Market
9. China Immunofluorescence Assay Market
10. India Immunofluorescence Assay Market
11. Japan Immunofluorescence Assay Market
12. Australia Immunofluorescence Assay Market
13. Indonesia Immunofluorescence Assay Market
14. South Korea Immunofluorescence Assay Market
15. Western Europe Immunofluorescence Assay Market
16. UK Immunofluorescence Assay Market
17. Germany Immunofluorescence Assay Market
18. France Immunofluorescence Assay Market
19. Italy Immunofluorescence Assay Market
20. Spain Immunofluorescence Assay Market
21. Eastern Europe Immunofluorescence Assay Market
22. Russia Immunofluorescence Assay Market
23. North America Immunofluorescence Assay Market
24. USA Immunofluorescence Assay Market
25. Canada Immunofluorescence Assay Market
26. South America Immunofluorescence Assay Market
27. Brazil Immunofluorescence Assay Market
28. Middle East Immunofluorescence Assay Market
29. Africa Immunofluorescence Assay Market
30. Immunofluorescence Assay Market Competitive Landscape and Company Profiles
31. Immunofluorescence Assay Market Other Major and Innovative Companies
35. Immunofluorescence Assay Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Immunofluorescence Assay Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on immunofluorescence assay market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for immunofluorescence assay? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immunofluorescence assay market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) Covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Direct Immunofluorescence; Indirect Immunofluorescence2) By Product: Reagents; Instruments; Antibodies; Kits; Consumables and Accessories
3) By Disease: Cancer; Infectious Disease; Cardiovascular Diseases; Autoimmune Diseases; Other Diseases
4) By End User: Academic and Research Institutions; Pharmaceutical and Biotechnology Companies; Contract Research Organizations; Hospitals and Diagnostic Centers
Subsegments:
1) By Direct Immunofluorescence: Single-Step Direct Assays; Multiplex Direct Assays2) By Indirect Immunofluorescence: Single-Step Indirect Assays; Multiplex Indirect Assays
Key Companies Mentioned: Thermo Fisher Scientific Inc.; Abcam plc; Bio-Rad Laboratories Inc.; PerkinElmer Inc.; Werfen Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Immunofluorescence Assay market report include:- Thermo Fisher Scientific Inc.
- Abcam plc
- Bio-Rad Laboratories Inc.
- PerkinElmer Inc.
- Werfen Company
- Merck KGaA
- Danaher Corporation
- Cell Signaling Technology Inc.
- Vector Laboratories Inc.
- INOVA Diagnostics Inc.
- Sino Biological Inc.
- Medipan GmbH
- BioLegend Inc.
- Jackson ImmunoResearch Laboratories Inc.
- Rockland Immunochemicals Inc.
- Bethyl Laboratories Inc.
- Fitzgerald Industries International Inc.
- Creative Diagnostics
- Boster Biological Technology
- Acris Antibodies GmbH
- RayBiotech Inc.
- Proteintech Group Inc.
- Novus Biologicals LLC
- R&D Systems Inc.
- OriGene Technologies Inc.
- GenScript Biotech Corporation
- MBL International Corporation
- Abnova Corporation
- Cellabs India Technologies Limited
- J. Mitra & Co. Pvt. Ltd.
- EpiGentek Group Inc.
- Elabscience Biotechnology Co. Ltd.
- Aesku.Diagnostics GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 3.59 Billion |
| Forecasted Market Value ( USD | $ 5.4 Billion |
| Compound Annual Growth Rate | 10.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 34 |
